Singular Genomics Systems (OMIC) Competitors $21.90 +0.38 (+1.77%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OMIC vs. CARA, FULC, SENS, QSI, SEER, FEIM, KEQU, AKYA, MASS, and OWLTShould you be buying Singular Genomics Systems stock or one of its competitors? The main competitors of Singular Genomics Systems include Cara Therapeutics (CARA), Fulcrum Therapeutics (FULC), Senseonics (SENS), Quantum-Si (QSI), Seer (SEER), Frequency Electronics (FEIM), Kewaunee Scientific (KEQU), Akoya Biosciences (AKYA), 908 Devices (MASS), and Owlet (OWLT). Singular Genomics Systems vs. Cara Therapeutics Fulcrum Therapeutics Senseonics Quantum-Si Seer Frequency Electronics Kewaunee Scientific Akoya Biosciences 908 Devices Owlet Singular Genomics Systems (NASDAQ:OMIC) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking. Do institutionals & insiders have more ownership in OMIC or CARA? 65.8% of Singular Genomics Systems shares are held by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are held by institutional investors. 22.2% of Singular Genomics Systems shares are held by insiders. Comparatively, 3.1% of Cara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor OMIC or CARA? Cara Therapeutics received 654 more outperform votes than Singular Genomics Systems when rated by MarketBeat users. Likewise, 72.98% of users gave Cara Therapeutics an outperform vote while only 44.83% of users gave Singular Genomics Systems an outperform vote. CompanyUnderperformOutperformSingular Genomics SystemsOutperform Votes1344.83% Underperform Votes1655.17% Cara TherapeuticsOutperform Votes66772.98% Underperform Votes24727.02% Which has stronger valuation & earnings, OMIC or CARA? Singular Genomics Systems has higher earnings, but lower revenue than Cara Therapeutics. Singular Genomics Systems is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSingular Genomics Systems$2.91M18.89-$94.82M-$35.11-0.62Cara Therapeutics$20.97M0.80-$118.51M-$1.75-0.17 Does the media refer more to OMIC or CARA? In the previous week, Cara Therapeutics had 2 more articles in the media than Singular Genomics Systems. MarketBeat recorded 3 mentions for Cara Therapeutics and 1 mentions for Singular Genomics Systems. Singular Genomics Systems' average media sentiment score of 0.96 beat Cara Therapeutics' score of -0.18 indicating that Singular Genomics Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Singular Genomics Systems 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, OMIC or CARA? Singular Genomics Systems has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Is OMIC or CARA more profitable? Cara Therapeutics has a net margin of -1,099.76% compared to Singular Genomics Systems' net margin of -3,237.89%. Singular Genomics Systems' return on equity of -57.87% beat Cara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Singular Genomics Systems-3,237.89% -57.87% -37.90% Cara Therapeutics -1,099.76%-367.97%-107.43% Do analysts recommend OMIC or CARA? Singular Genomics Systems currently has a consensus target price of $10.75, suggesting a potential downside of 50.91%. Cara Therapeutics has a consensus target price of $2.32, suggesting a potential upside of 660.66%. Given Cara Therapeutics' higher probable upside, analysts clearly believe Cara Therapeutics is more favorable than Singular Genomics Systems.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Singular Genomics Systems 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Cara Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummarySingular Genomics Systems and Cara Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Singular Genomics Systems News Delivered to You Automatically Sign up to receive the latest news and ratings for OMIC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMIC vs. The Competition Export to ExcelMetricSingular Genomics SystemsAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.97M$5.28B$5.07B$8.80BDividend YieldN/A0.47%4.99%4.07%P/E Ratio-0.627.1889.5613.60Price / Sales18.893.961,224.8087.40Price / CashN/A41.0639.4536.27Price / Book0.452.436.976.33Net Income-$94.82M$515,312.50$119.04M$225.93M7 Day Performance-3.74%-5.87%-1.78%-0.96%1 Month Performance45.03%-8.41%-3.59%1.06%1 Year Performance77.18%-17.17%31.64%26.59% Singular Genomics Systems Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMICSingular Genomics Systems1.915 of 5 stars$21.90+1.8%$10.75-50.9%+80.1%$54.97M$2.91M-0.62220CARACara Therapeutics3.9304 of 5 stars$0.31flat$2.32+660.7%-71.2%$16.73M$20.97M0.0055Analyst ForecastFULCFulcrum Therapeutics3.5645 of 5 stars$3.00+0.3%$9.33+211.1%-35.7%$161.82M$2.81M0.00100Analyst RevisionNews CoverageSENSSenseonics1.5915 of 5 stars$0.32-0.6%$2.00+534.3%-45.2%$186.86M$22.39M-2.4890Gap DownQSIQuantum-Si2.5603 of 5 stars$1.24-10.8%$3.25+162.1%-12.0%$176.54M$1.08M-1.94150Options VolumeAnalyst RevisionNews CoverageGap UpHigh Trading VolumeSEERSeer2.1857 of 5 stars$2.36+3.1%$3.00+27.1%+30.9%$139.17M$16.66M0.00160FEIMFrequency Electronics2.5737 of 5 stars$13.29+1.3%N/A+58.5%$127.19M$55.27M21.16200KEQUKewaunee Scientific1.1692 of 5 stars$42.18-0.9%N/A+136.4%$121.06M$203.76M6.831,006Positive NewsGap UpAKYAAkoya Biosciences1.7042 of 5 stars$2.20+1.9%$5.43+146.8%-50.8%$109.03M$96.63M0.0090Analyst ForecastMASS908 Devices2.772 of 5 stars$2.54-0.8%$8.00+215.0%-61.8%$88.44M$50.23M0.0060OWLTOwlet1.1758 of 5 stars$4.40-0.2%N/A-25.3%$70.58M$54M0.00106 Related Companies and Tools Related Companies CARA Competitors FULC Competitors SENS Competitors QSI Competitors SEER Competitors FEIM Competitors KEQU Competitors AKYA Competitors MASS Competitors OWLT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OMIC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Singular Genomics Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Singular Genomics Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
